3-methoxy-4-(4-methyl-1H-imidazol-1-yl)-N-[3-(trifluoromethyl)benzyl]benzamide | 1243203-54-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)-N-[3-(trifluoromethyl)benzyl]benzamide
• 英文别名: 3-methoxy-4-(4-methylimidazol-1-yl)-N-[[3-(trifluoromethyl)phenyl]methyl]benzamide
• CAS: 1243203-54-4
• 化学式: C₂₀H₁₈F₃N₃O₂
• 分子量: 389.377
• InChiKey: NKZYHNDTZFSDJC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  56.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  3-甲氧基-4-(4-甲基-1H-咪唑-1-基)苯甲腈 在 N,N-二异丙基乙胺 、 potassium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 90.0h， 生成 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)-N-[3-(trifluoromethyl)benzyl]benzamide
  参考文献：
  名称：

  Design and synthesis of dihydrobenzofuran amides as orally bioavailable, centrally active γ-secretase modulators

  摘要：

  We report the discovery and optimization of a novel series of dihydrobenzofuran amides as gamma-secretase modulators (GSMs). Strategies for aligning in vitro potency with drug-like physicochemical properties and good microsomal stability while avoiding P-gp mediated efflux are discussed. Lead compounds such as 35 and 43 have moderate to good in vitro potency and excellent selectivity against Notch. Good oral bioavailability was achieved as well as robust brain A beta 42 lowering activity at 100 mg/kg po dose. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.02.059

文献信息

• Novel Phenyl Imidazoles and Phenyl Triazoles As Gamma-Secretase Modulators
  申请人：Allen Martin Patrick

  公开号：US20120053165A1

  公开（公告）日：2012-03-01

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  本发明公开了具有式（I）所定义的结构的化合物及其药学上可接受的盐，同时公开了相应的制药组合物、治疗方法、合成方法和中间体。
• [EN] NOVEL AMIDE DERIVATIVE<br/>[FR] NOUVEAU DÉRIVÉ D'AMIDE
  申请人：DAINIPPON SUMITOMO PHARMA CO

  公开号：WO2011059048A1

  公开（公告）日：2011-05-19

  　本発明は、強いベータアミロイド４２産生抑制作用を有し、アルツハイマー病に代表されるベータアミロイドに起因する精神神経疾患の治療剤及び／又は予防剤として有用な新規化合物に関する。
• Design and synthesis of dihydrobenzofuran amides as orally bioavailable, centrally active γ-secretase modulators
  作者：Martin Pettersson、Douglas S. Johnson、Chakrapani Subramanyam、Kelly R. Bales、Christopher W. am Ende、Benjamin A. Fish、Michael E. Green、Gregory W. Kauffman、Ricardo Lira、Patrick B. Mullins、Thayalan Navaratnam、Subas M. Sakya、Cory M. Stiff、Tuan P. Tran、Beth C. Vetelino、Longfei Xie、Liming Zhang、Leslie R. Pustilnik、Kathleen M. Wood、Christopher J. O’Donnell

  DOI：10.1016/j.bmcl.2012.02.059

  日期：2012.4

  We report the discovery and optimization of a novel series of dihydrobenzofuran amides as gamma-secretase modulators (GSMs). Strategies for aligning in vitro potency with drug-like physicochemical properties and good microsomal stability while avoiding P-gp mediated efflux are discussed. Lead compounds such as 35 and 43 have moderate to good in vitro potency and excellent selectivity against Notch. Good oral bioavailability was achieved as well as robust brain A beta 42 lowering activity at 100 mg/kg po dose. (C) 2012 Elsevier Ltd. All rights reserved.